ONO Pharmaceutical Co., Ltd. 4528
TSE · Japan · Health Technology
¥2,333.00-13.50 (-0.58%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Ono Pharmaceutical Co. (OPHLF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Aitia will use its platform to analyse clinical and omics data and construct digital models for predictions.
The partnership gives Ono the exclusive option to license worldwide rights to develop the therapeutic programmes.
Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, has entered into a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") for novel treatments targeting fibro-inflammatory diseases. These diseases are characterized by myofibroblast activation, scarring, inflammation and tissue remodeling, which can lead to organ failure and compli
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.